Lumida
/RIGL
⌘K
Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

RIGL
$47.24USD-0.08%-0.04 today

MARKET CAP

882.4M

P/E (TTM)

12.0x

FWD P/E

15.3x

DAY RANGE

$47 – $48

52W RANGE

$25
$52

AI Summary

Stalk
StalkMedium

Despite the medium- and long-term bullish structure under a Stage 2 advance, extreme overbought conditions and an active Bullish Exhaustion pattern signal waning upside follow-through; deferred execution is advised, waiting for a pullback into the rising EMA support zone.

  • Q2 2026 net product sales $67M (+14% YoY)
  • Total Q2 revenues $78.7M; 2026 guidance $275–$290M
  • Intense oncology competition may limit market share gains
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$149.2M$120.2M$116.9M$179.3M$294.3M
YoY %+37.4%-19.4%-2.8%+53.4%+64.1%
P / Sales30.3x1.9x2.2x1.7x2.7x
EV / Sales31.1x2.9x3.1x2.2x3.0x
Gross Profit, Adj.$148.2M$118.5M$109.8M$160.6M$274.7M
YoY %+37.5%-20.0%-7.4%+46.3%+71.0%
Margin %99.3%98.5%93.9%89.6%93.3%
EV / Gross Profit31.3x3.0x3.3x2.5x3.2x
EBITDA, Adj.$-7.8M$-53.2M$-19.3M$26.4M$127.9M
YoY %+72.4%-581.3%+63.8%+237.2%+384.0%
Margin %-5.2%-44.3%-16.5%14.7%43.5%
EV / EBITDA-593.4x-6.6x-19.1x15.2x6.9x
EBIT$-12.5M$-55.5M$-20.5M$24.2M$125.5M
YoY %+56.9%-344.5%+63.1%+218.1%+418.6%
Margin %-8.4%-46.2%-17.5%13.5%42.6%
EV / EBIT-371.0x-6.3x-17.9x16.6x7.1x
Net Income$-17.9M$-58.6M$-25.1M$17.5M$367.0M
YoY %+39.8%-227.0%+57.2%+169.7%+1999.1%
Net Margin-12.0%-48.7%-21.5%9.8%124.7%
EPS (GAAP)-$0.11-$3.44-$1.44$0.99$19.48
YoY %+38.9%-3027.3%+58.1%+168.7%+1867.7%